1
|
Yao J, Wei L, Hao P, Liu Z, Wang P. Application of artificial intelligence model in pathological staging and prognosis of clear cell renal cell carcinoma. Discov Oncol 2024; 15:545. [PMID: 39390246 PMCID: PMC11467134 DOI: 10.1007/s12672-024-01437-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2024] [Accepted: 10/07/2024] [Indexed: 10/12/2024] Open
Abstract
This study aims to develop a deep learning (DL) model based on whole-slide images (WSIs) to predict the pathological stage of clear cell renal cell carcinoma (ccRCC). The histopathological images of 513 ccRCC patients were downloaded from The Cancer Genome Atlas (TCGA) database and randomly divided into training set and validation set according to the ratio of 8∶2. The CLAM algorithm was used to establish the DL model, and the stability of the model was evaluated in the external validation set. DL features were extracted from the model to construct a prognostic risk model, which was validated in an external dataset. The results showed that the DL model showed excellent prediction ability with an area under the curve (AUC) of 0.875 and an average accuracy score of 0.809, indicating that the model could reliably distinguish ccRCC patients at different stages from histopathological images. In addition, the prognostic risk model constructed by DL characteristics showed that the overall survival rate of patients in the high-risk group was significantly lower than that in the low-risk group (P = 0.003), and AUC values for predicting 1-, 3- and 5-year overall survival rates were 0.68, 0.69 and 0.69, respectively, indicating that the prediction model had high sensitivity and specificity. The results of the validation set are consistent with the above results. Therefore, DL model can accurately predict the pathological stage and prognosis of ccRCC patients, and provide certain reference value for clinical diagnosis.
Collapse
Affiliation(s)
- Jing Yao
- Department of Radiology, Tongji Hospital of Tongji University, Shanghai, 200065, China
- Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, 200065, China
| | - Lai Wei
- Department of Radiology, Tongji Hospital of Tongji University, Shanghai, 200065, China
- Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, 200065, China
| | - Peipei Hao
- Department of Radiology, Tongji Hospital of Tongji University, Shanghai, 200065, China
- Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, 200065, China
| | - Zhongliu Liu
- Department of Radiology, Tongji Hospital of Tongji University, Shanghai, 200065, China
- Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, 200065, China
| | - Peijun Wang
- Department of Radiology, Tongji Hospital of Tongji University, Shanghai, 200065, China.
- Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, 200065, China.
| |
Collapse
|
2
|
Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, Zhang Y, Zheng J. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res 2023; 189:106701. [PMID: 36796464 DOI: 10.1016/j.phrs.2023.106701] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 12/22/2022] [Accepted: 02/13/2023] [Indexed: 02/16/2023]
Abstract
Chimeric antigen receptor T-cell (CAR-T) is particularly prominent in hematological but not in solid tumors, mainly based on the complex tumor immune microenvironment. Oncolytic virus (OVs) is an emerging adjuvant therapy method. OVs may prime tumor lesions to induce anti-tumor immune response, thereby enhancing CAR-T cells functionality and possibly increasing response rates. Here, we combined CAR-T cells targeting carbonic anhydrase 9 (CA9) and an oncolytic adenovirus (OAV) carrying chemokine (C-C motif) ligand 5 (CCL5), cytokine interleukin-12 (IL12) to explore the anti-tumor effects of this combination strategy. The data showed that Ad5-ZD55-hCCL5-hIL12 could infect and replicate in renal cancer cell lines and induced a moderate inhibition of xenografted tumor in nude mice. IL12 mediated by Ad5-ZD55-hCCL5-hIL12 promoted the phosphorylation of Stat4 in CAR-T cells, induced CAR-T cells to secrete more IFN-γ. We also found that Ad5-ZD55-hCCL5-hIL-12 combined with CA9-CAR-T cells significantly increased the infiltration of CAR-T cells in tumor mass, prolonged the survival of the mice and restrained tumor growth in immunodeficient mice. Ad5-ZD55-mCCL5-mIL-12 could also increase CD45+CD3+T cell infiltration and prolong mice survival in immunocompetent mice. These results provided feasibility for the combination of oncolytic adenovirus and CAR-T cells, which demonstrated the sufficient potential and prospects of CAR-T for the treatment of solid tumors.
Collapse
Affiliation(s)
- Lin Fang
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China
| | - Weiping Tian
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China
| | - Chen Zhang
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Department of Oncology, The First People's Hospital of Yancheng, Jiangsu, China
| | - Xueyan Wang
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China
| | - Wanjing Li
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China
| | - Qi Zhang
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China
| | - Yuxin Zhang
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China
| | - Junnian Zheng
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
| |
Collapse
|
3
|
Lee Y, Park JH, Oh S, Shin K, Sun J, Jung M, Lee C, Kim H, Chung JH, Moon KC, Kwon S. Derivation of prognostic contextual histopathological features from whole-slide images of tumours via graph deep learning. Nat Biomed Eng 2022:10.1038/s41551-022-00923-0. [PMID: 35982331 DOI: 10.1038/s41551-022-00923-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 07/11/2022] [Indexed: 02/07/2023]
Abstract
Methods of computational pathology applied to the analysis of whole-slide images (WSIs) do not typically consider histopathological features from the tumour microenvironment. Here, we show that a graph deep neural network that considers such contextual features in gigapixel-sized WSIs in a semi-supervised manner can provide interpretable prognostic biomarkers. We designed a neural-network model that leverages attention techniques to learn features of the heterogeneous tumour microenvironment from memory-efficient representations of aggregates of highly correlated image patches. We trained the model with WSIs of kidney, breast, lung and uterine cancers and validated it by predicting the prognosis of 3,950 patients with these four different types of cancer. We also show that the model provides interpretable contextual features of clear cell renal cell carcinoma that allowed for the risk-based retrospective stratification of 1,333 patients. Deep graph neural networks that derive contextual histopathological features from WSIs may aid diagnostic and prognostic tasks.
Collapse
Affiliation(s)
- Yongju Lee
- Department of Electrical and Computer Engineering, Seoul National University, Seoul, Republic of Korea
| | - Jeong Hwan Park
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
| | - Sohee Oh
- Medical Research Collaborating Center, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
| | - Kyoungseob Shin
- Department of Electrical and Computer Engineering, Seoul National University, Seoul, Republic of Korea
| | - Jiyu Sun
- Medical Research Collaborating Center, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
| | - Minsun Jung
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Cheol Lee
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Hyojin Kim
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology and Translational Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Jin-Haeng Chung
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology and Translational Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Kyung Chul Moon
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
| | - Sunghoon Kwon
- Department of Electrical and Computer Engineering, Seoul National University, Seoul, Republic of Korea.
- Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea.
- Bio-MAX Institute, Seoul National University, Seoul, Republic of Korea.
- BK21+ Creative Research Engineer Development for IT, Seoul National University, Seoul, Republic of Korea.
- Biomedical Research Institute, Seoul National University, Seoul, Republic of Korea.
- Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul, Republic of Korea.
| |
Collapse
|
4
|
Zhang C, Fang L, Wang X, Yuan S, Li W, Tian W, Chen J, Zhang Q, Zhang Y, Zhang Q, Zheng J. Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma. Mol Ther Oncolytics 2022; 24:14-25. [PMID: 34977339 PMCID: PMC8688951 DOI: 10.1016/j.omto.2021.11.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 11/27/2021] [Indexed: 12/12/2022] Open
Abstract
Although chimeric antigen receptor T cell (CAR-T) therapy has been successful for hematological malignancies, it is less effective for solid tumors. The primary reason is that the immune microenvironment restricts CAR-T cells from infiltrating and proliferating in tumors. Oncolytic virotherapy has emerged as a novel immunogenic therapy to augment antitumor immune response. Here we combined an oncolytic adenovirus carrying decorin with a CAR-T targeting carbonic anhydrase IX (CAIX) to perform the antitumor activity for renal cancer cells. We found that OAV-Decorin combined with CAIX-CAR-T exhibited significantly reduced tumor burden, altered the composition of extracellular matrix (ECM) by inhibiting the distribution of collagen fibers, decreased the expression of TGF-β in tumor cells, enhanced IFN-γ secretion, and obtained higher numbers of CAR-T cells. The combination treatment modality showed prolonged mice survival. The intratumoral injection of OAV-Decorin into tumor-bearing immunocompetent mice activated the inflammatory immune status and resulted in tumor regression. These data supported further investigation of the combination of OAV-Decorin and CAIX-CAR-T cells in solid tumors.
Collapse
Affiliation(s)
- Chen Zhang
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China.,Department of Oncology, The First People's Hospital of Yancheng, Yancheng 224001 Jiangsu, China
| | - Lin Fang
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China.,Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - Xueyan Wang
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China
| | - Sen Yuan
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China
| | - Wanjing Li
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China
| | - Weiping Tian
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China
| | - Jing Chen
- Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - Qi Zhang
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China
| | - Yuxin Zhang
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China
| | - Qing Zhang
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China.,Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - Junnian Zheng
- Jiangsu Key Laboratory of Biological Cancer Therapy, Cancer Institute, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, China.,Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| |
Collapse
|
5
|
Editorial: Standard and future in the treatment of renal cell carcinoma. Curr Opin Urol 2021; 31:226-227. [PMID: 33769410 DOI: 10.1097/mou.0000000000000877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|